NextGen Healthcare and HMC/CAH Consolidated, Inc. Expand Relationship

HORSHAM, Pa.--NextGen Healthcare Information Systems, LLC., a wholly owned subsidiary of Quality Systems, Inc. (NASDAQ: QSII) and a leading provider of healthcare information systems and connectivity solutions, announced today it has forged an agreement with HMC/CAH Consolidated, Inc. (HMC). NextGen’s solutions will be deployed at five of HMC’s wholly owned Critical Access Hospitals; bringing 10 of HMC’s 12 rural community-based hospitals onto the NextGen Healthcare platform.

Under the agreement, Horton Community Hospital, Horton, Kan., Yadkin Valley Community Hospital, Yadkinville, N.C., Washington County Hospital, Plymouth, N.C., Hillsboro Community Medical Center, Hillsboro, Kan., and Oswego Medical Center, Oswego, Kan., will deploy NextGen® Inpatient Clinicals, NextGen® Lab and NextGen® Patient Portal to aid in the automation of medical processes as well as improvement of organizational efficiencies and to provide better quality care for patients while meeting Meaningful Use (MU) criteria for both Stage 1 and Stage 2.

An interoperable Hospital Electronic Health Record (EHR), NextGen Inpatient Clinicals is a highly scalable, secure and mobile-enabled platform designed to initiate widespread work efficiency and communication while reducing both errors and time-to-chart and improving the quality of care the hospital provides. It facilitates full electronic charting at the point-of-care, promotes interdisciplinary documentation and includes a discrete clinical data repository for customizable, comprehensive reporting thereby providing the capabilities to meet MU requirements.

“With five other HMC Critical Access Hospitals having already received Meaningful Use incentive dollars by leveraging NextGen solutions and expertise, we recognize first-hand that these additional five hospitals will be well-supported in their pursuit of Meaningful Use incentive revenue,” said Trent Skaggs, chief operating officer of Rural Community Hospitals of America (RCHA) who manages HMC’s 12 CAHs. “NextGen Healthcare offers a truly integrated solution that supports our hospitals’ mission to deliver the highest levels of quality care to the communities they serve and to advance their efforts to attest for MU."

“Rural and community hospitals face distinct challenges relevant to the adoption of healthcare IT and are precisely the type of facility to which NextGen Hospital Solutions caters,” said Jonathan Isaacs, senior vice president of Hospital Solutions for NextGen Healthcare. “Critical Access Hospitals need systems that offer the necessary flexibility and functionality for meeting evolving clinical and business needs. We are pleased to bring the benefits and customization capabilities of our technologies to these hospitals. Together, we will strive to enhance care, improve efficiencies and achieve better outcomes.”

About HMC/CAH Consolidated, Inc.

HMC/CAH Consolidated, Inc. (HMC) is a holding company which is in the business of acquiring and operating a system of acute care hospitals located in rural communities. The core focus of HMC's business plan is to replace the technologically out-of-date and operationally inefficient medical facilities of its Critical Access Hospitals with state-of-the-art facilities. Since its incorporation, HMC has purchased 12 rural hospitals certified as Critical Access Hospitals located in Kansas, Missouri, Tennessee and North Carolina.

About NextGen Healthcare

NextGen Healthcare Information Systems, LLC, a wholly owned subsidiary of Quality Systems, Inc., provides integrated clinical, connectivity and financial solutions, including revenue cycle management services for ambulatory, inpatient and dental provider organizations. For more information, please visit www.nextgen.com and www.qsii.com. Follow NextGen Healthcare on Twitter at www.twitter.com/nextgen, Facebook at http://www.facebook.com/NextGenHealthcare or LinkedIn at http://www.linkedin.com/company/nextgen-healthcare-information-systems.

Certain statements in this news release are forward-looking statements within the meaning of the federal securities laws, including but not limited to those statements related to future use of the Company’s products and statements made by Jonathan Isaacs related to the Company’s future products and offerings, and developments and trends in the healthcare industry. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Factors that could cause the anticipated results to differ from those described in the forward-looking statements include the possibility that products will not achieve or sustain market acceptance; the impact of incentive payments under The American Recovery and Reinvestment Act on sales and the ability of the Company to meet continued certification requirements; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in our software; changing economic, political or regulatory influences in the healthcare industry; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company's ability or inability to attract and retain qualified personnel; possible regulation of the Company's software by the U.S. Food and Drug Administration; and general economic conditions. Additional risks and uncertainties are set forth in the Company’s public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.